Weekly Funding Opportunities

[Med Research]

When Everyone Strives Foundation: Leukemia Research Grants<https://urldefense.com/v3/__https://www.wheneveryonesurvives.org/grant_application__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizD-lesK1s$ >
This request for proposals is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supports leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of “When Everyone Survives”.  Renewal of initial research support may be considered for one or more additional years based upon productivity. Awardees are required to submit a renewal request 60 days before your award end date.
Due June 1, 2020. Med-RA deadline to receive draft documents: May 18.

Mark Foundation for Cancer: Emerging Leader Award<https://urldefense.com/v3/__https://themarkfoundation.org/emerging-leader-award/__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDGb2LBS4$ >
The Mark Foundation Emerging Leader Awards support innovative research from the next generation of leaders in cancer research. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio. $250,000 per year for three years totaling $750,000; indirect costs  not to exceed $25,000 per year and are included in total.
Eligibility particularities include:

  *   Applicant must be three to eight years from the start of an independent faculty research appointment as of December 31, 2020 (i.e., the official start date of the appointment must fall within the calendar years 2012-2017). Exceptions due to prolonged medical or family leave will be considered on a case-by-case basis.
  *   This award is not intended to be the main source of funding for the applicant’s laboratory. Applicants must therefore demonstrate multi-year independent funding that sustains the central activities of the laboratory (e.g., at least one or two grants such as NIH/R01, NSF/CAREER, or equivalently substantial multi-year awards). Individual eligibility will be determined during the review stage.
Letter of intent due June 4, 2020. Med-RA deadline to receive draft documents: May 26.

Booz Allen Foundation COVID-19 Innovation Grant<https://urldefense.com/v3/__https://boozallenfoundation.org/innovationfund/?utm_source=media&utm_medium=pr&utm_campaign=BAF__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDwwP4Xt4$ >
The Booz Allen Foundation has established a $1 million Innovation Fund to help nonprofits, entrepreneurs, thought leaders, innovators at colleges and universities, and startups and small businesses harness the power of data, technology, and diverse intellectual capital to improve COVID-19 relief efforts and make a difference. We want to surface the most innovative solutions and empower the individuals and organizations behind those solutions to drive their development and implementation. Nonprofits can apply for grants of up to $100,000. Individuals, teams of individuals, and eligible for-profit organizations can apply for microgrants of up to $10,000. Through the Innovation Fund, the Foundation is specifically targeting solutions and projects that will build lasting community resilience through protecting vulnerable populations and frontline workers or providing for the safe return to work.
Due June 5, 2020. Med-RA deadline to receive draft documents: May 26.

NIH Research Project Grant (Parent R01)
R01 Clinical Trial Not Allowed<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/pa-20-185.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDKUpAXks$ >
R01 Clinical Trial Required<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizD4nguXqI$ >
The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26.

Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDwLLkw70$ >
This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-212.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDvwPFwBI$ > as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26.

NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-196.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDRXz1C90$ >
The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to inNOT-OD-18-212<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-212.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDvwPFwBI$ >as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3.

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required / Clinical Trial Not Allowed)
Parent R21 Clinical Trial Required<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDGDUgftg$ >
The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.
Parent R21 Clinical Trial Not Allowed<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDzG3PUe8$ >
The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3.

Management (NIHCM) Foundation Investigator-Initiated Health Services Research Grants<https://urldefense.com/v3/__https://www.nihcm.org/grants/research-grants__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDM7AHJ7A$ >
NIHCM Foundation supports innovative investigator-initiated research with high potential to inform improvements to the U.S. health care system. Projects must advance the existing knowledge base in the areas of health care financing, delivery, management and/or policy.
Letter of inquiry due June 29, 2020. Med-RA deadline to receive draft documents: June 16.

Congressionally Directed Medical Research Programs
Neurotoxin Exposure Treatment Parkinson's<https://urldefense.com/v3/__https://cdmrp.army.mil/funding/netp__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDcyKw2j0$ >
Early Investigator Research Award
Pre-application (letter of intent): August 18, 2020. Application: September 16, 2020.
Investigator Initiated Research Award
Pre-application (letter of intent): August 18, 2020. Application: September 16, 2020.
Synergistic Ideal Award
Pre-application (letter of intent): August 18, 2020. Application: September 16, 2020.
Med-RA deadline to receive draft documents for August 18 letter of intent deadline: August 10.

Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-180.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizD77hMO2I$ >
This Funding Opportunity Announcement invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs) and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanisms, and assessments of interactions between risk factors and interventions that address MCCs at different periods of the lifespan in diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encouraged. Studies may also include those that make use of existing data and/or data linkages to explore new research questions that may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring MCCs.
Standard dates apply. Expires September 8, 2023. Med-RA deadline to receive draft documents for first standard date deadline October 5, 2020: September 22.

Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-179.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizD3Rzds3I$ >
This Funding Opportunity Announcement invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs.
Standard dates apply. Expires September 8, 2023. Med-RA deadline to receive draft documents for first standard date deadline October 5, 2020: September 22.

Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 – Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-182.html__;!!PhOWcWs!nOZzNuwm4eQ_bCSTxv7WWzTY5Gp0KuYsBL3CrmdgaJClzkUkIzADCmKJLSLaq7-6DJ1RZczEMizDDYtUnHU$ >
This funding opportunity announcement aims to support research that employs innovative scalable technologies to identify, map, and profile cellular ensembles and/or cell-types that produce and/or respond to opioids or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on approaches that enable high-throughput single-cell resolution mapping, anatomical characterization and/or molecular profiling of cells identified as targets of, or as primary sources of opioids in the brain.
Due October 30, 2020. Med-RA deadline to receive draft documents: October 19.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.



-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200511/36f317db/attachment.html>